Literature DB >> 26476560

Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models.

Noorazrul Yahya1, Martin A Ebert2, Max Bulsara3, Michael J House4, Angel Kennedy5, David J Joseph6, James W Denham7.   

Abstract

BACKGROUND AND
PURPOSE: This study aimed to compare urinary dose-symptom correlates after external beam radiotherapy of the prostate using commonly utilised peak-symptom models to multiple-event and event-count models which account for repeated events.
MATERIALS AND METHODS: Urinary symptoms (dysuria, haematuria, incontinence and frequency) from 754 participants from TROG 03.04-RADAR trial were analysed. Relative (R1-R75 Gy) and absolute (A60-A75Gy) bladder dose-surface area receiving more than a threshold dose and equivalent uniform dose using exponent a (range: a ∈[1 … 100]) were derived. The dose-symptom correlates were analysed using; peak-symptom (logistic), multiple-event (generalised estimating equation) and event-count (negative binomial regression) models.
RESULTS: Stronger dose-symptom correlates were found for incontinence and frequency using multiple-event and/or event-count models. For dysuria and haematuria, similar or better relationships were found using peak-symptom models. Dysuria, haematuria and high grade (⩾ 2) incontinence were associated to high dose (R61-R71 Gy). Frequency and low grade (⩾ 1) incontinence were associated to low and intermediate dose-surface parameters (R13-R41Gy). Frequency showed a parallel behaviour (a=1) while dysuria, haematuria and incontinence showed a more serial behaviour (a=4 to a ⩾ 100). Relative dose-surface showed stronger dose-symptom associations.
CONCLUSIONS: For certain endpoints, the multiple-event and event-count models provide stronger correlates over peak-symptom models. Accounting for multiple events may be advantageous for a more complete understanding of urinary dose-symptom relationships.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Event-count model; Multiple-event model; Normal tissue complications; Prostate radiotherapy; Urinary symptoms

Mesh:

Year:  2015        PMID: 26476560     DOI: 10.1016/j.radonc.2015.10.003

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

Review 1.  Inclusion of dosimetric data as covariates in toxicity-related radiogenomic studies : A systematic review.

Authors:  Noorazrul Yahya; Xin-Jane Chua; Hanani A Manan; Fuad Ismail
Journal:  Strahlenther Onkol       Date:  2018-05-17       Impact factor: 3.621

2.  Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy.

Authors:  Sangkyu Lee; Sarah Kerns; Harry Ostrer; Barry Rosenstein; Joseph O Deasy; Jung Hun Oh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-31       Impact factor: 7.038

3.  Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.

Authors:  Calyn R Moulton; Michael J House; Victoria Lye; Colin I Tang; Michele Krawiec; David J Joseph; James W Denham; Martin A Ebert
Journal:  Radiat Oncol       Date:  2016-10-31       Impact factor: 3.481

4.  Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method.

Authors:  Makito Miyake; Nobutaka Nishimura; Yasushi Nakai; Tomomi Fujii; Takuya Owari; Shunta Hori; Yosuke Morizawa; Daisuke Gotoh; Satoshi Anai; Kazumasa Torimoto; Nobumichi Tanaka; Yoshihiko Hirao; Kiyohide Fujimoto
Journal:  Diagnostics (Basel)       Date:  2021-01-28

5.  Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials.

Authors:  Marco Marcello; James W Denham; Angel Kennedy; Annette Haworth; Allison Steigler; Peter B Greer; Lois C Holloway; Jason A Dowling; Michael G Jameson; Dale Roach; David J Joseph; Sarah L Gulliford; David P Dearnaley; Matthew R Sydes; Emma Hall; Martin A Ebert
Journal:  Front Oncol       Date:  2020-07-22       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.